Carole Nuechterlein Net Worth

The estimated Net Worth of Carole Nuechterlein is at least $11.7 Milhão dollars as of 25 October 2023. Ms. Nuechterlein owns over 7,933,601 units of Millendo Therapeutics stock worth over $11,687,497 and over the last 9 years she sold MLND stock worth over $0. In addition, she makes $0 as Independent Director at Millendo Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Nuechterlein MLND stock SEC Form 4 insiders trading

Carole has made over 1 trades of the Millendo Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 7,933,601 units of MLND stock worth $6,029,537 on 25 October 2023.

The largest trade she's ever made was buying 7,933,601 units of Millendo Therapeutics stock on 25 October 2023 worth over $6,029,537. On average, Carole trades about 721,236 units every 0 days since 2016. As of 25 October 2023 she still owns at least 11,025,941 units of Millendo Therapeutics stock.

You can see the complete history of Ms. Nuechterlein stock trades at the bottom of the page.

Carole Nuechterlein biography

Carole L. Nuechterlein J.D. serves as Independent Director of the Company. Ms. Nuechterlein joined F. Hoffmann-La Roche Ltd. in 2001 and currently serves as a Deputy Director and head of Roche Venture Fund. Prior to that, from 1998 to 2001, Ms. Nuechterlein served as General Counsel for SangStat, Inc., a biopharmaceutical company. Ms. Nuechterlein has also served as a member of the boards of directors of a number of private companies, including each of Aligos Therapeutics, a biotechnology company, since August 2018, Vivet Therapeutics SAS, a biotechnology company, since April 2017, CiVi BioPharma, Inc., a biopharmaceutical company, since March 2017, Lumos Pharma, Inc., a biopharmaceutical company, since January 2017, Mission Therapeutics Ltd., a biopharmaceutical company, since January 2017, Arch Oncology Inc., a biopharmaceutical company, since August 2016, Second Genome, Inc., a biopharmaceutical company, since April 2016, and Lysosomal Therapeutics Inc., a biotechnology company, since May 2014. She also served as a member of the board of directors of AveXis Inc., a biotechnology company (Nasdaq: AVXS), from October 2014 to May 2017. Ms. Nuechterlein received a B.A. from Valparaiso University and a J.D. from University of Michigan.

How old is Carole Nuechterlein?

Carole Nuechterlein is 59, she's been the Independent Director of Millendo Therapeutics since 2018. There are 2 older and 9 younger executives at Millendo Therapeutics. The oldest executive at Millendo Therapeutics, Inc. is John Howe, 77, who is the Independent Director.

What's Carole Nuechterlein's mailing address?

Carole's mailing address filed with the SEC is C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080.

What does Millendo Therapeutics do?

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

Complete history of Ms. Nuechterlein stock trades at Millendo Therapeutics e Aligos Therapeutics

Millendo Therapeutics executives and stock owners

Millendo Therapeutics executives and other stock owners filed with the SEC include:

• Julia Owens,
  President, Chief Executive Officer, Director
• Louis Arcudi,
  Chief Financial Officer
• Ryan Zeidan,
  Chief Development Officer
• Dr. Julia C. Owens Ph.D.,
  Exec. Chair of Board
• Louis J. Arcudi III, M.B.A., MBA,
  CEO, Pres & Director
• Carol Gallagher,
  Independent Chairman of the Board
• Connie Chang,
  Vice President - Corporate Affairs
• Carole Nuechterlein,
  Independent Director
• John Howe,
  Independent Director
• James Hindman,
  Independent Director
• Mary Hedley,
  Independent Director
• Habib Dable,
  Independent Director
• Geoffrey Nichol,
  Independent Director
• Thomas Hoover,
  Chief Commercial Officer
• Christophe Arbet-Engels,
  Chief Medical Officer
• Tamara Joseph,
  General Counsel, Corporate Secretary
• Denise Dorigo Jones,
  VP of HR
• Jeffery M. Brinza J.D.,
  Interim Gen. Counsel
• Jennifer Lynn Minai-Azary,
  CFO & Principal Accounting Officer
• Jeffery M. Brinza,
  Sec., CAO and General Counsel
• Randall W Whitcomb,
  Director
• Pharis Mohideen,
  Chief Medical Officer
• Jennifer Lynn Minai Azary,
  Chief Financial Officer